您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Halopemide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Halopemide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Halopemide图片
CAS NO:59831-65-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
Halopemide 是一种有效的磷脂酶 D (PLD) 抑制剂,对人 PLD1 和 PLD2 的 IC50 分别为 220 和 310 nM。
Cas No.59831-65-1
别名卤培米特,NSC 354856,R34301
化学名N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-ethyl]-4-fluoro-benzamide
Canonical SMILESClC1=CC2=C(N(C3CCN(CCNC(C4=CC=C(F)C=C4)=O)CC3)C(N2)=O)C=C1
分子式C21H22ClFN4O2
分子量416.9
溶解度≤10mg/ml in DMSO;20mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 220 and 310 nM for human PLD1 and PLD2, respectively

Halopemide is a phospholipase D (PLD) inhibitor.

Phospholipase D (PLD) is a key enzyme for the production of phosphatidic acid, a lipid second messenger. Phosphatidic acid involves in both G protein-coupled receptor and receptor tyrosine kinase signal transduction networks.

In vitro: In a previous study, the IC50 of halopemide against PLD2 was found to be similar to that previously reported, but the compound had no preference for PLD2 over PLD1 [1].

In vivo: Animal study showed that the halopemide concentration in the rat brain was 10 times less than that of R29800, its chemical analog. However, the levels were the same in the pituitary gland. The highest level of halopemide was found to be in septal and thalamic areas while the neuroleptics were concentrated in the caudate nucleus. Moreover, in the caudate nucleus, halopemide was far less particle-bound [2].

Clinical trial: The activating and resocializing properties of halopemide were evaluating in an open and double-blind study in patients with various psychiatric disorders. The results showed a significant improvement in contact and activity, regardless of the nosological characteristics. Moreover, no significant difference in therapeutic effect between the single and the double dose was found [3].

References:
[1] Scott, S. A.,Selvy, P.E.,Buck, J.R., et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nature Chemical Biology 5(2), 108-117 (2009).
[2] Loonen AJ, van Wijngaarden I, Janssen PA, Soudijn W.  Regional localization of halopemide, a new psychotropic agent, in the rat brain. Eur J Pharmacol. 1978 Aug 15;50(4):403-8.
[3] De Cuyper H, van Praag HM, Verstraeten D. The clinical significance of halopemide, a dopamine-blocker related to the butyrophenones. Neuropsychobiology. 1984;12(4):211-6.